Recent media reports from Pakistan suggest that Imran Khan, the former Prime Minister and World Cup-winning captain, has reportedly lost nearly 85% of vision in his right eye due to central retinal ...

June 24, 2009 — On June 17, the US Food and Drug Administration (FDA) approved a dexamethasone 0.7-mg intravitreal implant (Ozurdex, Allergan, Inc) for the treatment of macular edema after branch ...

On October 26, 2023, Genentech, a member of the Roche Group, announced that the FDA approved VABYSMO (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). RVO is ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo ...

Patients with retinal vein occlusion who received Vabysmo experienced visual improvements as well as extended treatment intervals at 72 weeks, according to a study. At Angiogenesis, Exudation, and ...

In both studies, Vabysmo was found to be noninferior to aflibercept, with average vision gains being comparable between the treatment groups. The Food and Drug Administration (FDA) has approved ...

Closing in on a likely approval to treat retinal vein occlusion (RVO), Roche has presented long-term data that show Vabysmo can maintain visual gains in the indication with a dosing duration stretched ...

Please provide your email address to receive an email when new articles are posted on . The European Commission approved Vabysmo for the treatment of visual impairment due to macular edema secondary ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...

– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...